Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 5/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1075551 | 0.88 | PRKDC (0.34) | NT5EPRKDCHDAC8 | |
| SCHEMBL1078559 | 0.83 | NT5E (0.33) | NT5E | |
| SCHEMBL1078555 | 0.83 | NT5E (0.33) | NT5E | |
| SCHEMBL1077450 | 0.81 | MEN1 (0.30) | — | |
| SCHEMBL1035934 | 0.80 | FTO (0.35) | — | |
| SCHEMBL1077140 | 0.78 | HSP90AA1 (0.33) | — | |
| SCHEMBL1076073 | 0.77 | ESR1 (0.31) | — | |
| SCHEMBL2307448 | 0.73 | NT5E (0.38) | NT5EPRKDC | |
| SCHEMBL1075552 | 0.72 | NT5E (0.32) | NT5EPRKDC | |
| SCHEMBL1076317 | 0.72 | NT5E (0.32) | NT5EPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276732-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KAROBIO AB (SE) | 2015-05-20 | — | — | EP | claimed |
| US-8653072-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-02-18 | — | — | US | claimed |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | KARO BIO AB (SE) | 2013-05-23 | — | — | US | claimed |
| US-8367665-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2013-02-05 | — | — | US | claimed |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | OASMIA PHARMACEUTICAL AB (SE) | 2011-08-04 | — | — | US | claimed |
| EP-2276732-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-01-26 | — | — | EP | claimed |
| WO-2009127686-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-10-22 | — | — | WO | claimed |
| EP-3782616-B1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3782616-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | The Regents of The University of California (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3189026-B1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| EP-2276732-B1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KAROBIO AB (SE) | 2015-05-20 | — | — | EP | disclosed |
| US-8653072-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2014-02-18 | — | — | US | disclosed |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | KARO BIO AB (SE) | 2013-05-23 | — | — | US | disclosed |
| US-8367665-B2 | Estrogen receptor ligands | KARO BIO AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | OASMIA PHARMACEUTICAL AB (SE) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304216-A1 | ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES | ESR2, ESRRG, ESR1 | HDAC4 1286/4885NT5E 2244/4885HDAC9 1892/4885 |
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | HDAC4 1286/4885NT5E 2244/4885HDAC9 1892/4885 |
| US-20130131061-A1 | Novel Estrogen Receptor Ligands | ESR1, GPER1, ESRRA | HDAC4 664/4885NT5E 3983/4885HDAC9 952/4885 |
| US-20110190294-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, GPER1, ESRRA | HDAC4 563/4885NT5E 4052/4885HDAC9 887/4885 |
| US-10758496-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | HDAC4 1286/4885NT5E 2244/4885HDAC9 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.